Northwest Bioth New (NWBO) Stock News

USA - Nasdaq - NASDAQ:NWBO -

0.57

-0.13 (-18.57%)

Last: 12/16/2016, 8:10:00 PM

0.53

-0.04 (-7.02%)

After Hours: 12/16/2016, 8:10:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NWBO Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility

a month ago - By: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed

3 months ago - By: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

4 months ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

6 months ago - By: Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

a year ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

a year ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

a year ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

2 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

3 years ago - By: Northwest Biotherapeutics

News Image

Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

3 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB

3 years ago - By: BusinessInsider - Mentions: N

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

3 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

3 years ago - By: InvestorPlace - Mentions: GME AMC BBBY

NWBO Stock Alert: Northwest Bio Slams Citadel Securities in New Lawsuit

3 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

3 years ago - By: Benzinga - Mentions: NLST DSGT ONEQ FMCC ...

A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know

3 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

3 years ago - By: Benzinga - Mentions: BTC GBTC NLST ETH ...

These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month

3 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility

3 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program

4 years ago - By: Northwest Biotherapeutics

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

4 years ago - By: Northwest Biotherapeutics

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

4 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

4 years ago - By: PennyStocks.com - Mentions: EDU FAMI

Looking for Penny Stocks to Buy Now? 3 to Know About as 2021 Ends

4 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

4 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces $15 Million Financing

4 years ago - By: Northwest Biotherapeutics

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility